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ÖZET
Amaç: Bu çalışmanın amacı valsartan ve nebivololun an-
tihipertansif etkilerini ve bu ilaçların hipertansif hastaların 
tedavisinde QT dağılımı ve sol ventrikül hipertrofisi üzeri-
ne etkilerini analiz etmektir.
Yöntemler: Sol ventrikül hipertrofisi (SVH) bulunan ha-
fif/orta hipertansiyonlu hastalarda 6 ay süreli takip içe-
ren prospektif bir çalışma düzenlendi. Hastalar rastgele 
olarak Valsartan (80-160 mg/gün) veya Nebivolol (5-10 
mg/gün) gruplarına alındı. Çalışma grubu 55’i Valsartan 
grubu, 53’ü Nebivolol grubunda olmak üzere toplam 108 
hastadan oluşturuldu.
Bulgular: Valsartan grubunda ortalama sistolik kan ba-
sıncı  (SKB)  152±17  mmHg  (bazal)’den  132±17  mmHg 
(takip)’e değişti (p<0.001). Nebivolol grubunda ise orta-
lama  SKB,  146±13  mmHg  (bazal)’den  125±14  mmHg 
(takip)’e değişti (p<0.001). Valsartan grubunda ortalama 
diyastolik kan basıncı (DBP) azalması 9.5±2.5 mmHg ve 
Nebivolol grubunda 12.3±5.0 mmHg idi. Her iki grupta da 
QT ve düzeltilmiş QT (Bazett formülü) dağılımında anlamlı 
azalma gözlendi ve bu azalma Valsartan grubunda hafif-
çe daha fazla idi. Ekokardiyografi sol venrikül kitle (SVK) 
indekslerinde Valsartan grubunda daha fazla azalma ile 
birlikte her iki grupta azalmayı gösterdi (p<0.05). 
Sonuç: Valsartan tedavisi 24 saatlik SKB’ında 6 aylık te-
davi ile Nebivolol kadar etkili bulundu. Nebivolol tedavisi 
DKB’ını düşürmede Valsartan tedavisine üstün bulundu. 
Her iki tedavi SVH’sini azaltmada etkili idi. Valsartan kan 
basıncı ve SVK’de azalmayla birlikte QT aralık indeksle-
rinde azaltmada Nebivolole üstün bulundu.
Anahtar  kelimeler:  Hipertansiyon,  elektrokardiyografi, 
sol ventrikül hipertrofisi, QT aralığı, ekokardiyografi
ABSTRACT
Objectives: The aim of this study was to analyze the an-
tihypertensive effect of Valsartan and Nebivolol and their 
effects on QT dispersion and left ventricular hypertrophy 
(LVH) in the treatment of naive hypertensive patients.
Methods: A prospective study with a six-month follow-up 
was conducted on hypertensive patients with LVH and 
mild/ moderate essential hypertension. The patients were 
randomly assigned to Valsartan (80 to 160 mg/day) or 
Nebivolol (5 to 10 mg/day) groups. The study group con-
sisted of 108 patients, 55 in the Valsartan group and 53 in 
the Nebivolol group. 
Results:  The  range  of  mean  systolic  blood  pressure 
(SBP) varied from 152±17 (baseline) to 132±17 mmHg 
(follow-up) in the Valsartan group (p<0.001); from 146±13 
to 125±14 mmHg in the Nebivolol group (p<0.001). The 
decrease  in  mean  diastolic  blood  pressure  (DBP)  was 
9.5±2.5  mmHg  in  the  Valsartan  group  and  12.3±5.0 
mmHg in the Nebivolol group. A significant reduction in 
QT and corrected QT (Bazett’s formula) dispersion was 
observed in both groups, with a slightly higher reduction 
in the Valsartan group. Echocardiography showed a de-
crease in the left ventricle mass (LVM) indices (p<0.05) 
in both groups with a greater reduction in the Valsartan 
group.
Conclusion:  Valsartan  treatment  was  as  effective  as 
Nebivolol in reducing the 24 hour- SBP after a 6 month 
treatment. Nebivolol treatment proved to be superior to 
Valsartan in reducing DBP. Both therapies were effective 
in reducing the LVH; Valsartan proved to be superior to 
Nebivolol in reducing the QT interval indexes in relation to 
blood pressure and LVM reduction.
Key words: Hypertension, electrocardiography, left ven-
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INTRODUCTION
In  hypertensive  patients,  the  left  ventricular  hy-
pertrophy  (LVH)  predicts  an  increased  morbidity 
and mortality, sudden death being up to 10 times 
more prevalent in individuals with LVH than those 
without LVH1. In the Framingham Study, LVH was 
recognized as a strong, virtually independent risk 
factor2.
The QT interval is the surface Electrocardio-
graphic (ECG) representation of the action potential 
duration in the ventricle and prolongation of the QT 
interval has been associated with an increased risk 
of  ventricular  tachycardia  and  sudden  death3.  Its 
standard clinical correction [Bazett’s formula4 QTc] 
is used in order to adjust this interval by the heart 
rate. The QT interval duration has also been found 
to predict all causes and cardiac mortality in hyper-
tensive subjects with LVH5 and QTc dispersion ap-
pears to be a valid predictor of arrhythmias6.
An effective antihypertensive treatment, may 
improve the non-invasive electrocardiographic pa-
rameters in addition to the control of arrhythmias 
and regression of LVH7,8.
Valsartan is part of the class of angiotensin II 
receptor  blockers  (ARBs).  The  benefits  of  ARB 
therapy of hypertension go beyond the reduction in 
blood pressure (BP). Additional advantages include 
a decrease in ventricular arrhythmias9 or a reduc-
tion in the abnormal QT dispersion10. Valsartan has 
proved to have a favourable safety and efficacy pro-
file and represents a good option for a wide range of 
hypertensive patients11.
Nebivolol has proved to be as efficient as any 
other antihypertensive drugs (e.g. calcium channels 
blockers,  angiotensin-converting  enzyme  (ACE) 
inhibitors, and older ß-blockers12-14. Nebivolol is a 
highly selective β1-adrenergic receptor blocker with 
vasodilating action through stimulation of endothe-
lial nitric oxide (NO) bioactivity15,16. Nebivolol has 
proved to be as efficient as any other antihyperten-
sive drugs (e.g. calcium channels blockers, angio-
tensin-converting  enzyme  (ACE)  inhibitors,  and 
older ß-blockers12-14. It also has a good tolerability 
and fewer adverse events compared with older beta-
blockers15,16.
Two  therapeutic  strategies  (Valsartan  and 
Nebivolol, administered once daily) were applied 
to treatment naive hypertensive patients, with ECG 
and echocardiographic evidence of LVH.
In present study, the effects of Valsartan and 
Nebivolol on BP, LVH and index of QT interval, 
corrected  for  heart-rate  QT  interval  (QTc),  were 
analyzed and compared.
PATIENTS AND METHODS
A prospective randomized, parallel-group study was 
conducted at the Diagnosis and Treatment Centre, 
Cluj-Napoca, Romania. The study was approved by 
the Ethics Committee of the “Iuliu Haţieganu” Uni-
versity  of  Medicine  and  Pharmacy  Cluj-Napoca, 
and all subjects gave informed consent for partici-
pation in the study.
Consecutive  eligible  adult  outpatients  of  ei-
ther sex with mild or moderate hypertension (office 
sitting SBP of 140-179 mmHg and/or office DBP 
90-109 mmHg, defined according to international 
guidelines  (18))  and  echocardiographic  LVH  de-
fined as left ventricular mass index ≥ 134 g/m² for 
men and ≥ 110 g/m² for women19, were included in 
the study. Patients were enrolled between November 
2004 and August 2007 and had never been treated 
as hypertensive patients (naive to antihypertensive 
drug  treatment).  The  patients  were  prospectively 
followed-up for 6 months. Patients were excluded 
from the study if they had any of the following: ma-
lignant and known or suspected secondary hyperten-
sion; clinically significant heart disease (coronary 
heart disease, major arrhythmias, cardiac valvular 
defects, heart failure); concomitant cerebrovascu-
lar, renal, hepatic diseases, diabetes, haematologi-
cal and malignant diseases, psychiatric disorders, 
obesity (BMI>30kg/m2), pregnancy and known or 
suspected hypersensitivity to ARB or β blockers.
The patients that complied with the inclusion 
criteria were randomly assigned to one of the two 
treatment groups: Valsartan or Nebivolol the first 
patient being assigned to the Valsartan group and 
the second to the Nebivolol group. The study was 
not blind, both patient and physician were famil-
iar with the used drugs. The starting dose was 80 
mg for Valsartan and 5 mg Nebivolol, once daily in 
the morning (as recommended in the international 
guidelines18. The doses were doubled (160 mg for 
Valsartan and 10 mg for Nebivolol) in patients with 
inadequate BP control (office SBP ≥ 140 mmHg or L. Latea et al. Effects of valsartan and nebivolol 83
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office DBP ≥ 90 mmHg, after 4 to 6 weeks of treat-
ment with the initial doses). The medical history of 
each patient was recorded; physical examination, 
office BP measurement and 12-lead electrocardio-
grams  were  performed  at  the  screening  visit. At 
the study initiation and at the final visit, twenty-
four-hour  ambulatory  BP  monitoring  computed 
LVMI19,20,  M-mode  echocardiography,  computed 
LVMI, twenty-four hour ECG recordings for com-
puting the QT and QTc were performed.
The office BP was measured using a standard 
sphygmomanometer, with the patient seated for at 
least 10 minutes. For the office BP reference value, 
the mean of 3 measurements at rest in the sitting 
position was used.
The ambulatory blood pressure (ABPM) was 
monitored with ABPM-04, 99/BP411 - Medibase. 
Before  the  beginning  of  ABPM,  blood  pressure 
was measured with a mercury sphygmomanometer, 
with the patient seated for at least 10 minutes. The 
arm with higher BP values at sphygmomanometer 
evaluation was chosen for ABPM. In order to re-
duce errors during the day, all patients were asked to 
ensure that the arm was always parallel to the trunk 
when the cuff was inflated. Readings were obtained 
automatically at 15 minutes interval from 6:00 am 
to 10:00 pm and 30 minutes interval from 10:00 pm 
to 6:00 am. All the measurements were performed 
by the same investigator, using the same equipment, 
both at the beginning of the study and during the 
follow up.
All  patients  underwent  24  hour  ambulatory 
ECG  recording  with  a  three  channel  (Cardiospy 
system  Holter  ECG,  recorder  type  3CH+PM). A 
single investigator, blinded to other measurements 
and treatment assignment, checked the automatic 
measurements of QT interval indexes. Appropriate 
corrections of cursor location were made and trac-
ings in which the T wave was isoelectric or of too 
low amplitude for accurate determination of the end 
point, were excluded.
Echocardiography was performed with the pa-
tient in the supine left lateral decubitus position. The 
echocardiographic  investigations  were  performed 
by the same investigator, using the same equipment 
(ESAOTE  MyLab,  3.5-MHz  transducer),  both  at 
the beginning of the study and during the follow up. 
The M-mode echocardiographic evaluation of the 
left ventricle was performed under 2-dimensional 
control. Measurements were taken according to the 
American Society of Echocardiography recommen-
dations20. The following measurements were made 
for  each  patient:  intraventricular  septal  thickness 
(IVSTd),  posterior  wall  thickness  (PWTd),  end-
diastolic diameter (LVIDd), and end-systolic diam-
eter (LVISd). The left ventricular mass was calcu-
lated using the Devereux and Reichek formula21: 
LVM=1.04• ((IVSTd+ PWTd + LVIDd) ³- (LVIDd) 
³) - 13.6 g. The left ventricular mass index (LVMI) 
was determined by dividing LV mass by body sur-
face area.
All ABPM, ambulatory ECG and echocardio-
graphic parameters were determined at the begin-
ning of the study and after 6 months of Valsartan 
or Nebivolol therapy. All patients received regular 
therapy during the follow-up period.
Statistical Analysis
The values of the quantitative variables were ex-
pressed as means ± SD (standard deviation); the 
values of qualitative variables were expressed as a 
percentage with associated 95% confidence inter-
vals [binomial distribution formula] 22,23.
Changes from baseline in QT indexes (QT dis-
persion, QT maxim, QTc maxim, and QTc disper-
sion), BP and LVMI measurements were analyzed 
using the Student t test after investigation of the 
normality  distribution.  When  the  normality  was 
not accomplished a non-parametric test was used to 
compare the results (Mann-Whitney: two indepen-
dent-samples  test,  Wilcoxon:  two-related-samples 
test). The Z test for comparison of the equality of 
two proportions was applied whenever appropriate. 
Pearson’s correlation coefficient was applied to as-
sess the relationship between changes from base-
line systolic blood pressure (SBP), diastolic blood 
pressure (DBP), left ventricular mass index and the 
change from baseline QTd and corrected QT disper-
sion values. A p value < 0.05 was considered statis-
tically significant.
Statistical analyses were performed by using 
SPSS 12.0.
RESULTS
One hundred and eight eligible patients (48 men 
– 95%, CI (35.19 – 54.62), 60 women – 95% CI 
(45.38-64.81)) were randomized to either Valsartan L. Latea et al. Effects of valsartan and nebivolol 84
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(n = 55) or Nebivolol (n = 53) once daily. The demographic and baseline clinical characteristics of the two 
groups are presented in Table 1. All patients included in the study completed the 6 months follow-up.
Table 1. Baseline demographic and clinical characteristics by treatment group
Variable
Treatment group
 p-value
Valsartan Nebivolol
Gender: absolute frequency (percentage)
Male 20 (36.4%) 28 (52.8%) 0.0783
Female 35 (63.6%) 25(47.2%) 0.0783
Age: means±SD
Male (years) 57.85±14.12 58.04±10.44 0.9590
Female (years) 62.11±11.94 60.07±14.94 0.5490
BMI 27.44±4.93 28.42±4.37 0.2790
Mean 24h SBP (mmHg) 152.56±16.87 145.58±13.04 0.0180
Mean 24h DBP (mmHg) 86.87±11.71 83.21±13.44 0.1330
QT dispersion (ms) 74.71±4.65 74.28±5.42 0.6620
QT max (ms) 442.35±18.13 438.09±22.21 0.2780
QT min (ms) 373.22±15.13 363.81±20.76 0.1660
QTc max(ms)  511.65±27.17 519.28±33.67 0.1960
QTc min(ms) 433.93±24.74 441.30±33.26 0.1770
QTc dispersion (ms) 77.71±6.11 77.98±6.51 0.8230
LVMI (g/m²) 173.16±25.28 165.43±25.10 0.1140
SD: Standard deviation, BMI: Body mas index, QT 
max: Maximal QT interval, 
QT  min:  Minimal  QT  interval,  QTc  max:  Maximal 
corrected QT interval, QTc min: Minimal corrected 
QT interval , LVMI: Left ventricular mass index
Nine  characteristics,  baseline  vs.  follow-up, 
were  compared  on  each  treatment  group:  Mean 
SBP, ∆SBP, Mean DBP, ∆DBP, QT max, dQT, QTc 
max, dQTc, and LVMI. The results expressed as 
mean value and associated standard deviations as 
well as the p-values for the mean comparisons are 
presented by treatment groups in Table 2.
In all 108 patients with valid ambulatory BP 
recordings,  24-hour  SBP  and  DBP  values  were 
significantly (p<0.05) reduced by both treatments 
compared  to  baseline  values. After  6  months  of 
treatment, SBP reduction rates were significant and 
similar in both treatment groups but there was a 
higher reduction observed in DBP in the Nebivolol 
group (Table 2).
After 6 months of treatment, there was a statis-
tically significant reduction in QT indexes (QT dis-
persion, QTc dispersion, QT max, QTc max) in the 
Valsartan and Nebivolol group compared to base-
line values (Table 2).
The difference of the SBP mean on follow-up 
evaluation  was  revealed  as  significantly  statisti-
cal when the Valsartan and Nebivolol groups were 
compared (p= 0.034). The same was observed also 
for DBP mean (p=0.006).
No significant differences between the inves-
tigated  groups  were  identified  in  comparison  of 
LVMI at baseline and follow-up (baseline p=0.114; 
follow-up p=0.450).
The correlation between the change in QT dis-
persion and BP and LVMI in both treatment groups 
are presented in Table 3.L. Latea et al. Effects of valsartan and nebivolol 85
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Table 2. Treatment group comparison of mean changes from baseline parameters (mean±SD)
Parameter
Valsartan Group Nebivolol Group
pre-treat post-treat p pre-treat post-treat p
Mean SBP 152.56±16.87 131.67±17.17 < 0.001 145.58±13.04 125.25±13.64 < 0.001
∆SBP n.a. 20.89±4.39 n.a. n.a. 20.34±4.53 n.a.
Mean DBP 86.87±11.71 77.36±11.74 < 0.001 83.21±13.44 70.91±12.17 < 0.001
∆DBP n.a. 9.50±2.48 n.a. n.a. 12.30±4.99 n.a.
QT max 442.35±18.13 425.64±19.17 <0.001 438.09± 22.21 429.38±22.34 <0.001
QT min 373.22±15.23 359.24±16.48 <0.001 363.81±20.76 360.10±23.28 <0.001
dQT 74.71±4.65 66.38±5.13 <0.001 74.28±5.42 69.28±6.76 <0.001
QTc max 511.65±27.17 496.25±28.28 <0.001 519.28±33.67 508.40±32.26 <0.001
QTc min 433.93±24.74 429.22±26.50 <0.001 441.30±33.26 434.85±31.72 <0.001
dQTc  77.71±6.11 67.04±6.85 <0.001 77.98±6.51 73.55±7.38 <0.001
LVMI 173.16±25.28 156.51±24.68 <0.001 165.43±25.10 152.91±24.72 <0.001
n.a.: Not applicable, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, QT max: Maximal QT 
interval, QT min: Minimal QT interval, dQT: QT interval dispersion, QTc max: Maximal corrected QT inter-
val, QTc min: Minimal corrected QT interval, dQTc: Corrected QT interval dispersion, LVMI: Left ventricular 
mass index
pared to baseline values in both treatment groups 
(Valsartan 80 to 160mg/day vs. Nebivolol 5-10 mg/
day) without previous antihypertensive treatment.
Both drugs were associated with comparable 
reductions in 24h SBP, but Nebivolol proved to re-
duce the DBP significantly compared to Valsartan. 
This result is in accordance with other studies; a 
greater effect of Nebivolol on DBP but not on SBP 
compared to Losartan was also observed24.
Valsartan treatment proved to determine a sig-
nificant reduction of QTd and QTc dispersion com-
pared to Nebivolol in treated patients.
In hypertensive patients with no evidence of 
coronary disease the most important sudden cardiac 
death cause is ventricular arrhythmia5,25. In hyper-
tensive patients an important correlation between 
sudden cardiac death and an increased value of QT 
dispersion5 was observed and it was demonstrated 
that different antihypertensive treatments decrease 
the QT dispersion and reduce arrhythmias10,26,27.
It is well known that antihypertensive treatments 
which inhibit the renin angiotensin system (RAAS) 
decrease also the QT dispersion in hypertension10,28. 
In the same way in the present study ARB (Valsar-
tan)  treatment,  showed  a  significant  decrease  of 
QTd and QTc in hypertensive patients. ARB’s have 
Table 3. Pearson correlation coefficients between 
change in BP, QT interval dispersion and LVMI from 
baseline with treatment
Parameters
Group
Valsartan Nebivolol
∆SBP-QT dispersion 0.516** 0.307*
∆SBP-QTc dispersion 0.251* 0.542**
∆DBP-QT dispersion 0.471** 0.368**
∆DBP-QTc dispersion 0.309* 0.525**
LVMI-QT dispersion 0.650** 0.715**
LVMI-QTc dispersion 0.294* 0.470**
LVMI-∆SBP 0.580** 0.435**
LVMI-∆DBP 0.561** 0.382**
 *p<0.01; ** p<0.001
DISCUSSION
Two drugs were investigated in the treatment of na-
ive patients with mild or moderate essential hyper-
tension by ambulatory assessment of BP; ECG and 
LVMI were used as primary end points.
In this study, after a 6 month treatment, mean 
24h SBP, mean 24 hDBP, QT max, QTc max, QTd, 
QTc  dispersion  and  LVMI  were  decreased  com-L. Latea et al. Effects of valsartan and nebivolol 86
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been proved to reduce the LVMI this being one of 
the most important causes of the QTd decrease. In 
left ventricular hypertrophy (LVH) directly linked 
to myocardial fibrosis and increase of ventricular 
premature  beats  and  re-entry  activity,  ventricular 
tachycardia and sudden cardiac death occur. LVH 
increases the action potential duration and the risk of 
ventricular tachycardia and sudden cardiac death29.
In arterial hypertension and Holter ECG docu-
mented arrhythmias, the risk of sudden cardiac death 
increases. In a study by Galinier et al., Lown class 
IIb in Holter ECG, and QTd > 80 ms were signifi-
cantly related to global, cardiac and sudden death 
(p < 0.01)30. Elevated QT interval dispersion was 
associated with more severe ventricular arrhythmias 
in hypertensive patients with LVH. The mechanism 
of  an  increased  inhomogeneity  of  repolarization, 
represented by QT interval and QT dispersion, was 
considered to be related to anatomic modifications 
induced by LVH25.
Experimental  studies  have  demonstrated  that 
Angiotensin II has arrhythmogenic effects on the 
cardiac  system.  Literature  data  supports  the  idea 
that  inhibition  of  the  rennin  angiotensin  system 
protects heart and other organs from hypertensive 
complications31.
Arrhythmias can occur in LVH when the re-
polarization homogeneity is altered but the rennin 
angiotensin system (RAS) and sympathetic nervous 
system (SNS) are closely interrelated32. Thus, the 
inhibition of SNS could be responsible for the de-
crease of QTd by ARB33. Moreover, the β blocker 
therapy has proved to decrease QTd especially in 
patients with left ventricular systolic dysfunction34.
The effects of Nebivolol treatment on QT dis-
persion  in  hypertensive  patients  with  LVH  were 
evaluated by Galetta et al.35. The authors observed 
that Nebivolol reduced QT dispersion in hyperten-
sive subjects after four weeks of treatment. This ef-
fect occurred without any change in LVH, did not 
seem to be related to the lowering of the blood pres-
sure and could contribute to reduce arrhythmias as 
well as sudden cardiac death in at risk hypertensive 
patients36. In contrast, in the present study Nebiv-
olol reduced QTd from baseline values and also re-
duced LVMI. 
Nebivolol is a highly selective ß1-adrenergic 
receptor blocker with vasodilating action through 
stimulation of endothelial nitric oxide (NO) bioac-
tivity37. Nebivolol also has been shown to increase 
the left ventricular performance and improve the 
coronary flow reserve38.
In the present study, the effects of both thera-
pies on QT indexes were related to BP and LVMI 
decrease.  Because  the  after  load  increases,  myo-
cardial stress is raised and can induce the risk of 
spontaneous depolarization. In this study the QTd 
decrease was related to the after load reduction, this 
being  the  possible  mechanism  implied.  Another 
mechanism is that the activation on SNC is a cause 
of after depolarization and can increase the hetero-
geneous repolarization39.
Antihypertensive treatment with Valsartan and 
Nebivolol reduces the heterogeneous repolarization 
and could help to reduce the ventricular arrhythmias 
risk and the risk of sudden cardiac death. Valsar-
tan treatment proved to be superior over Nebivolol 
treatment in reducing the heterogeneous repolariza-
tion by BP reduction and LVH reduction.
The small sample size of subjects was the main 
limitation of the study. The investigation of the pa-
tients on a single centre study and also the method 
used for randomization could be considered also a 
limitation of the present study. A more extensive 
study is required.
Conclusion
In this study, in a small sample of treatment naive 
hypertensive patients, the antihypertensive effect on 
SBP of Valsartan 80-160 mg was not significantly 
different from that of Nebivolol 5-10 mg. It can be 
concluded based on the obtained results that Valsar-
tan 80 to 160mg/day was as effective as 5-10 mg/
day of Nebivolol in reducing the 24h systolic but 
not in reducing the diastolic BP during 6 months 
of treatment in patients with mild or moderate es-
sential hypertension without previous antihyperten-
sive treatment. Nebivolol provided a significantly 
greater reduction of DBP compared to Valsartan. 
The effect on LVH of both treatments was not sig-
nificantly different. Valsartan proved to be superior 
to Nebivolol with a significantly greater reduction 
of QT and QTc dispersion in relation to the BP and 
LVMI reduction.L. Latea et al. Effects of valsartan and nebivolol 87
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